Start the conversation
The big caps like Apple and Google are terrific performers, don't get me wrong, but they just can't hold a candle to small-cap gains.
I love small caps because they offer the potential for runaway, triple-digit profits that you can bank as the companies you've picked grow… and grow some more.
These kinds of gains aren't random. They're triggered by "sparks," catalysts that I watch for that can propel stocks upward.
In the case of the biotech stock I'm about to show you, there were a whopping five sparks present.
And, even better, there's likely almost 440% more in gains left for the taking…
A Novel Way to Fight a Deadly Threat
Rockville, Md.-based Novavax Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical company. It can deliver a novel vaccine candidate in just a matter of weeks using its innovative Recombinant Nanoparticle Technology – synthetic genes to create nanoparticle vaccines to cure (or improve immunity to) a particular disease. And Novavax does it with a level of precision and efficiency that has never existed before.
Until Novavax, traditional vaccine manufacturing required researchers to grow an actual virus, obtain an embryonated chicken egg, and adapt the virus or optimize new strains to grow in eggs. This process takes a long time.
It also puts researchers at risk of infection and requires high-tech facilities to ensure the virus is contained at all times.
But Novavax vaccines are developed, from inception, using synthetic virus genes. That means researchers are safe from contamination as they work. Additionally, the Novavax method implements a disposable, single-use manufacturing system – eliminating the need to clean and sterilize equipment between batches. That means an antivirus production facility can be built at a fraction of the cost traditional methods require.
Because the company can produce affordable safe vaccines, it can build regional facilities in area hotspots. So-called "local" sourcing is a huge advantage. It means customers don't have to rely on foreign suppliers that are subject to import/export regulations and miles of bureaucratic red tape that slows down effective pandemic treatment.
Novavax's system is much cheaper, safer, and faster.
In an age where deadly pandemics can travel just as easily as people can, which is to say dang near anywhere on the planet in 24 hours, you can see how this disruptive technology gives Novavax a serious leg-up over competitors, which still have to work with dangerous live viruses in a process that can take months to play out.
About the Author
Sid is the investment community's best-kept secret. Since 2009, he's served at Money Map Press as Director of Research, analyzing thousands of securities and profit opportunities for subscribers. He's an expert in identifying "alpha" potential in a wide variety of industries, but especially the small-cap sector, where he's discovered a pattern of profits that's almost foolproof.